June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Integrin peptide inhibitor for the treatment of intermediate Age Related Macular Degeneration
Author Affiliations & Notes
  • Hugo Quiroz-Mercado
    Research Department, Asociación para Evitar la Ceguera en México I.A.P., Mexico City, Mexico
  • Jose Luis Guerrero-Naranjo
    Retina , Asociación para Evitar la Ceguera en Mexico I.A.P., Mexico City, Mexico
  • Roberto Gonzalez-Salinas
    Research Department, Asociación para Evitar la Ceguera en México I.A.P., Mexico City, Mexico
  • Luis F Hernandez-Zimbron
    Research Department, Asociación para Evitar la Ceguera en México I.A.P., Mexico City, Mexico
  • Ruben Zamora
    Research Department, Asociación para Evitar la Ceguera en México I.A.P., Mexico City, Mexico
  • Rosario Gulías-Cañizo
    Research Department, Asociación para Evitar la Ceguera en México I.A.P., Mexico City, Mexico
  • Lenin Ochoa-De la Paz
    Research Department, Asociación para Evitar la Ceguera en México I.A.P., Mexico City, Mexico
  • Lisa Karageozian
    Allegro Ophthalmics LLC, San Juan Capistrano, California, United States
  • Vicken Karageozian
    Allegro Ophthalmics LLC, San Juan Capistrano, California, United States
  • Linda Kutscher
    Allegro Ophthalmics LLC, San Juan Capistrano, California, United States
  • John Y Park
    Allegro Ophthalmics LLC, San Juan Capistrano, California, United States
  • Hampar Karageozian
    Allegro Ophthalmics LLC, San Juan Capistrano, California, United States
  • Footnotes
    Commercial Relationships   Hugo Quiroz-Mercado, None; Jose Luis Guerrero-Naranjo, None; Roberto Gonzalez-Salinas, None; Luis F Hernandez-Zimbron, None; Ruben Zamora, None; Rosario Gulías-Cañizo, None; Lenin Ochoa-De la Paz, None; Lisa Karageozian, Allegro Ophthalmics LLC (E); Vicken Karageozian, Allegro Ophthalmics LLC (E); Linda Kutscher, Allegro Ophthalmics LLC (E); John Park, Allegro Ophthalmics LLC (E); Hampar Karageozian, Allegro Ophthalmics LLC (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1943. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Hugo Quiroz-Mercado, Jose Luis Guerrero-Naranjo, Roberto Gonzalez-Salinas, Luis F Hernandez-Zimbron, Ruben Zamora, Rosario Gulías-Cañizo, Lenin Ochoa-De la Paz, Lisa Karageozian, Vicken Karageozian, Linda Kutscher, John Y Park, Hampar Karageozian; Integrin peptide inhibitor for the treatment of intermediate Age Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1943.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Purpose
Luminate® is a first-in-class integrin-inhibitor and has been shown to have treatment effects for both vitreolysis and angiogenesis. To date, more than 400 subjects with DME and VMT have been treated by intravitreal treatment with positive efficacy and an excellent safety profile. Proteomics and genomic testing at Caltech has suggested a potential neuroprotective effect which could treat other retinal diseases. The purpose of this probe study was to evaluate any possible effect of Luminate® on patients with intermediate dry AMD.

Methods : Methods
This case series was IRB approved and required signed informed consent. This was a prospective, interventional, case series. Main inclusion criteria involved dry macular degeneration eyes with relatively intact photoreceptor and RPE layers in the central 1mm by OCT. Baseline BCVA was between 20/30 and 20/200 with no evidence of subretinal fluid or CNV and no history of anti-VEGF treatment. All recruited patients underwent a baseline single intravitreal injection of Luminate® 1.0 mg and were monitored monthly over a 6-month follow-up. A central macular thickness OCT, digital color photos and BCVA pre and post treatment were obtained.

Results : Results.
A total of 5 patients (five eyes) were included in this probe study. All 5 patients completed a minimal 3-month follow-up. Results obtained were as follows: In patient 1, BCVA improved form 0.5 to 0.3 logMAR; patient 2 improved from 1.0 to 0.6 logMAR; patient 3 improved from 1.3 to 1.0 logMAR and patient 4 improved from 0.2 to 0.1 logMAR respectively. Mean BCVA changed from 0.75 ± 0.52 (~20/100) at baseline to 0.66 ± 0.4 (~20/60) logMAR at 3-month examination.
One patient (patient 5) did not experience a change in visual acuity. All five patients subjectively reported more vivid colors and brighter images in their vision. There was a tendency for BCVA improvement.

Conclusions : Conclusions
In a small pilot study, Luminate® increased BCVA in four of five eyes with intermediate dry AMD. This is the first clinical study showing improvement in BCVA by intravitreal Luminate therapy. Future studies with larger cohorts of study subjects and double masked controls is warranted. In future studies, objective anatomic analysis of drusen, auto-fluorescence, and multifocal ERGs would also provide useful guidance on study design and treatment.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×